$NVTA News

Last published 1y ago

1y agoNVTACitizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered HealthcarePR NewswireCitizen Health, a patient-powered platform transforming rare disease care, announced today it has raised $30 million in Series A funding. The round...
2y agoNVTA BBIOInvitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease TherapeuticsPR NewswireInvitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a...
2y agoNTRA NVTANatera Acquires Reproductive Health Assets from InvitaeBusiness WireNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE:NVTA), a leading medical genetics company, certain assets relating to Invitae's
2y agoNVTA NTRAInvitae Completes Sale of Reproductive Health Assets to NateraPR NewswireInvitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which...
2y agoNVTAInvitae Divests Ciitizen Health Data Platform and Implements Further Cost CutsPR NewswireInvitae (NYSE: NVTA), a leading medical genetics company, today announced strategic changes to streamline operations and reduce operating cash burn....
2y agoNVTAAranscia Acquires YouScript from InvitaeBusiness WirePioneering Pharmacogenomics Platform Joins Portfolio of Complementary Precision Medicine Workflow Solutions Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae
3y agoNVTAInvitae Corporation (NVTA) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoNVTAInvitae Reports Third Quarter 2023 Financial ResultsPR NewswireInvitae (NYSE: NVTA), a leading medical genetics company, today announced results for the third quarter ended September 30, 2023. "The Company...
3y agoNVTAInvitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research PartnershipsPR NewswireInvitae (NYSE: NVTA), a leading medical genetics company, today announced enhanced chemistry of its Invitae Personalized Cancer Monitoring™ platform...
3y agoNVTAInvitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023PR NewswireInvitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2023 financial results on Wednesday,...
3y agoNVTALandmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive ResultsPR NewswireInvitae (NYSE: NVTA), a leading medical genetics company, today announced findings from the largest study to date on uncertain results from...
3y agoNVTAInvitae Appoints Dr. David Sholehvar as Chief Operating OfficerPR NewswireInvitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar, M.D., as...
3y agoNVTARural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast CancerPR Newswire– Invitae retrospective analysis reinforces the clinical actionability of following the ASBrS guidelines – – Testing results informed clinical management and suggest that genetics-informed care may improve patient
3y agoNVTAInvitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical GenomicsPR Newswire- Sponsor of the Heart of Genetic Counseling program and award, recognizing excellence in patient care - - These studies combined with new digital tools aim to increase access and frequency of hereditary cancer screening
3y agoNVTAInvitae's Common Hereditary Cancers Panel Receives FDA Market AuthorizationPR Newswire– First-of-its-kind authorization provides potential marketing differentiation and opportunities for largest testing category – – Testament to Invitae's product and lab quality – – Sets the bar for expected
3y agoNVTAFDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer TypesFDA Press ReleasesToday, the U.S. Food and Drug Administration granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, an in vitro diagnostic test that can help detect hundreds of genetic variants associated with an elevated risk of developing certain cancers. The test can also help identify potentially cancer-associated hereditary variants in individuals with already-diagnosed canc ...
3y agoNVTAInvitae Announces Appointment of Finance Veteran Ana Schrank as CFOPR NewswireSAN FRANCISCO, Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO),
3y agoNVTAInvitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing StandardPR NewswireSAN FRANCISCO, Sept. 22, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it received a notice from the New York Stock Exchange (the "NYSE") on September 20,
3y agoNVTAClinical Trial Results Support Genetic Testing of All Patients with Prostate CancerPR Newswire– Research published in European Urology Oncology shows restrictive genetic testing criteria miss a significant number of prostate cancer patients with potentially actionable inherited variants – – Offering germline
3y agoNVTAInvitae Announces Selection of Finance Executive Robert Dickey as Interim CFOPR Newswire– Christine Gorjanc resumes role as Chair of the Audit Committee of the Board of Directors for Invitae – SAN FRANCISCO, Aug. 14, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today
3y agoNVTAInvitae Reports Second Quarter 2023 Financial ResultsPR Newswire– Reported revenue of $120.5 million, a 12% year-over-year decrease due to exited businesses and geographies; pro forma revenue up slightly year-over-year – – GAAP gross margin was 27.4% and non-GAAP gross margin was
3y agoNVTAInvitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023PR NewswireSAN FRANCISCO, July 26, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023, and will
3y agoNVTAInvitae Corporation (NVTA) Annual William Blair Growth Stock Conference CallEarnings Call Transcripts
3y agoNVTAAltoida Appoints Marc Jones as Chief Executive OfficerBusiness WireAltoida, Inc, a pioneer in developing digital biomarkers of neurological disease using augmented reality and machine learning, announced today the appointment of industry veteran Marc Jones as Chief Executive Officer.
3y agoNVTAInvitae to Present at the William Blair 43rd Annual Growth Stock ConferencePR NewswireSAN FRANCISCO, May 31, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that Ken Knight, president and chief executive officer, will present at the William Blair 43rd Annual
3y agoNVTANew Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in OncologyPR Newswire– Study findings confirm the importance of improving education among clinicians and streamlining processes to increase adoption of testing in routine cancer care – SAN FRANCISCO, May 26, 2023 /PRNewswire/
3y agoNVTAInvitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFOPR NewswireSAN FRANCISCO, May 25, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that Chief Financial Officer (CFO) Yafei (Roxi) Wen is resigning to pursue other opportunities,
3y agoNVTAInvitae to Appeal Trial VerdictPR NewswireSAN FRANCISCO, May 15, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it intends to appeal the verdict delivered by a jury at the United States District Court for the
3y agoNVTAInvitae Reports First Quarter 2023 Financial ResultsPR Newswire– Reported revenue of $117.4 million, a 5% year-over-year decrease due to exited businesses and geographies; pro forma year-over-year revenue growth was ~10% – – Continued improvement in gross margin and ongoing cash
3y agoNVTAInvitae to Announce First Quarter 2023 Financial Results on Tuesday, May 9, 2023PR NewswireSAN FRANCISCO, April 26, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023, and will host a
3y agoNVTAInvitae Publishes Annual Environmental, Social and Governance (ESG) ReportPR Newswire– Report details the company's commitment to improve healthcare for all through its ESG and sustainability initiatives – SAN FRANCISCO, April 17, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics
3y agoNVTANew Study Findings Published in Nature Show Circulating Tumor DNA (ctDNA) Can Predict and Detect Cancer Recurrence Earlier In Non-Small Cell Lung CancerPR Newswire– Highlights the use of Invitae's personalized cancer monitoring (PCM) technology to correlate clinical outcomes with minimal residual disease (MRD) presence – – The analysis demonstrates the utility of ctDNA as a
3y agoNVTAInvitae and Deerfield Management Partner to Create Novel Therapeutics for Rare DiseasesPR Newswire– The partnership will harness genetic and clinical data from millions of patients tested at Invitae and Deerfield's expertise in drug discovery to address high unmet needs among rare disease patients – SAN
3y agoNVTAInvitae Announces Partnership with Epic to Streamline Genetic TestingPR Newswire– Collaboration will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine – SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a
3y agoNVTAInvitae Appoints Dr. W. Michael Korn as Chief Medical Officer for OncologyPR Newswire– Expert in the field of gastrointestinal cancer and precision oncology to lead Invitae's medical oncology team with a particular focus on somatic testing development – – Invitae reports inducement grant under NYSE
3y agoNVTAInvitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic TestingPR Newswire– New research looking at underrepresented racial, ethnic and ancestry groups underscores the importance of universal germline genetic testing – SAN FRANCISCO, March 15, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a
3y agoNVTAInvitae's PCM Assay for Minimal Residual Disease Receives its First Commercial CoveragePR Newswire– Blue Shield of California has over 3 million covered members in CA – SAN FRANCISCO, March 6, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that its Personalized Cancer
3y agoNVTAInvitae to Present at the TD Cowen 43rd Annual Health Care ConferencePR NewswireSAN FRANCISCO, March 1, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that Ken Knight, president and chief executive officer, will participate in a fireside chat at the TD
3y agoNVTAInvitae Announces Convertible Notes and Share Exchange and New Convertible Notes IssuancePR Newswire– In a transaction led by Deerfield Management, the Company effectively addresses ~96% of its 2024 convertible debt obligations – – Participating holders to exchange 90% of their existing 2024 notes for new notes due in
3y agoNVTAInvitae Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Company UpdatesPR Newswire– Entered into a ~$336 million transaction for the 2024 convertible notes, effectively addressing ~96% of the amount outstanding (see separate press release to follow) – – Repaid its 2024 senior secured term loan in
3y agoNVTAInvitae (NVTA) Q4 2022 Earnings Call TranscriptEarnings Call TranscriptsNVTA earnings call for the period ending December 31, 2022.
3y agoNVTAInvitae to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023PR NewswireSAN FRANCISCO, Feb. 14, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28,
3y agoNVTAInvitae Appoints William H. Osborne to its Board of DirectorsPR Newswire– Brings invaluable expertise in leading, operating and scaling global businesses throughout his career in aerospace, transportation and integrated solutions – SAN FRANCISCO, Jan. 30, 2023 /PRNewswire/
3y agoNVTAInvitae Reports Preliminary 2022 Financial ResultsPR Newswire— Approximately 12% growth year-over-year in revenues —— Greater than $555 million in cash, cash equivalents, marketable securities, and restricted cash —— Cash burn continued its declining trend over the past five
3y agoNVTAInvitae to Present at the 41st Annual J.P. Morgan Healthcare ConferencePR NewswireSAN FRANCISCO, Jan. 4, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that Ken Knight, president & chief executive officer, will present at the 41st Annual J.P. Morgan
3y agoNVTAIntegrated DNA Technologies Acquires ArcherDX Next Generation Sequencing Research Assays from Invitae CorporationBusiness WireAddition of next generation sequencing research panels, bioinformatics, positions IDT to become a leading oncology research solutions provider Integrated DNA Technologies, Inc. (IDT) today announced it closed on the
3y agoNVTAInvitae Completes Selected Assets Sale of its Next Generation Sequencing (NGS) research assays to Integrated DNA Technologies, Inc.PR Newswire— Invitae will continue to invest in its precision oncology focused lab developed test (LDT) offerings — — The transaction contributes to Invitae's cash runway and includes a strategic supply partnership to support
3y agoNVTAInvitae Executive Appointed to National Health Information Technology Advisory CommitteePR Newswire– Deven McGraw to serve a 3-year term beginning in 2023 – SAN FRANCISCO, Dec. 19, 2022 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, announced the appointment by the U.S. Government
3y agoNVTAInvitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic ResearchPR Newswire– Invitae to report on secondary patient data use, demonstrating real-world impact of de-identified patient data on the advancement of precision medicine – – Company achieves over 1 million ClinVar submissions to advance
3y agoNVTAInvitae Launches Rare Patient Network for Pediatric Patients With Rare Neurodevelopmental DiseasesPR Newswire– Ciitizen real-world data platform expansion helps advance research and potentially improve outcomes for patients with pediatric epilepsy and/or developmental delay – SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Invitae